Venous Thromboembolism - Pipeline Insight, 2024

Venous Thromboembolism - Pipeline Insight, 2024

DelveInsight’s, “Venous Thromboembolism – Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Venous Thromboembolism pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Venous Thromboembolism Understanding

Venous Thromboembolism: Overview

Venous Thromboembolism (VTE) is the third most common cardiovascular disease worldwide and is the most common avoidable cause of hospital death. VTE encompasses two conditions: deep vein thrombosis (DVT) and pulmonary embolism (PE). DVT is a blood clot that forms in the veins that lie deep within the muscles, for example in the leg or pelvis. If all or part of the DVT breaks off and the blood clot moves to block a vessel in the lungs, this is known as a PE, an event which can be rapidly fatal. Symptoms of DVT include: pain, swelling, redness of the affected area, usually the leg and the skin may also be warm to the touch. Symptoms of PE include: acute shortness of breath, chest pain, rapid heart rate, some people may also cough blood.

""Venous Thromboembolism - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Venous Thromboembolism pipeline landscape is provided which includes the disease overview and Venous Thromboembolism treatment guidelines. The assessment part of the report embraces, in depth Venous Thromboembolism commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Venous Thromboembolism collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Venous Thromboembolism R&D. The therapies under development are focused on novel approaches to treat/improve Venous Thromboembolism.

Venous Thromboembolism Emerging Drugs Chapters

This segment of the Venous Thromboembolism report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Venous Thromboembolism Emerging Drugs

• Isoquercetin: Quercis Pharma

Isoquercetin (ISQ950AN) is a patented formulation which prevents platelet activation and initiation of the thrombotic cascade. The safety of an investigational drug has been proven in various studies, with no serious side effects having been identified. The focus is on prevention of venous thrombosis and pulmonary embolism in high risk cancer patients with our drug candidate ISQ950AN. Quercis Pharma is working with the CRO Clinipace in a Phase III trial of Kinisoquin (isoquercetin) for venous thromboembolism (VTE) prevention in pancreatic cancer patients. The FDA told Quercis that if it successfully shows efficacy in two separate Phase III studies for two separate cancer types, isoquercetin would be able to apply for registration in VTE prevention for all types of cancers. A Phase II/III for Isoquercetin has been completed.

• Abelacimab: Anthos therapeutics

Abelacimab, with its novel dual activity against Factor XI and XIa, has the potential to turn the vision of hemostasis-sparing anticoagulation into reality. Within this emerging class of Factor XI inhibitors, abelacimab – a highly selective, fully human monoclonal antibody – stands out due to its novel dual activity against both Factor XI and its activated form, Factor XIa. This dual activity enables profound suppression of Factor XI activity. Phase I and II clinical studies confirmed that a single 150mg dose of abelacimab (intravenous or subcutaneous) effectively suppresses Factor XI for at least 30 days. It is planned to be available as a rapid-onset intravenous presentation to prevent VTEs in the inpatient setting and a once-monthly subcutaneous version for ongoing protection in the community, with the anticipation of improved adherence.

Further product details are provided in the report……..

Venous Thromboembolism: Therapeutic Assessment

This segment of the report provides insights about the different Venous Thromboembolism drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Venous Thromboembolism

There are approx. 10+ key companies which are developing the therapies for Venous Thromboembolism. The companies which have their Venous Thromboembolism drug candidates in the most advanced stage, i.e. Phase II/III include, Quercis Pharma.

• Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Venous Thromboembolism pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Venous Thromboembolism: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Venous Thromboembolism therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Venous Thromboembolism drugs.

Venous Thromboembolism Report Insights

• Venous Thromboembolism Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Venous Thromboembolism Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Venous Thromboembolism drugs?
• How many Venous Thromboembolism drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Venous Thromboembolism?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Venous Thromboembolism therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Venous Thromboembolism and their status?
• What are the key designations that have been granted to the emerging drugs?